Scope of the Study
Hydroxychloroquine is a derivative of chloroquine that has both antimalarial and anti-inflammatory activities. It is used to prevent or treat malaria caused by mosquito bites. It is treated malaria by killing the parasites that cause the disease. It is also used to treat certain auto-immune diseases such as lupus and rheumatoid arthritis. India manufactures 70% of the world's supply of hydroxychloroquine, according to Indian Pharmaceutical Alliance (IPA). United States Food and Drug Administration has identified Hydroxychloroquine as a possible treatment for COVID-19. The studies showed that it shortens the time to clinical recovery of COVID-19 patients. The study conducting in France enrolling 80 patients showed that Hydroxychloroquine alone or in combination with Azithromycin appeared to reduce virus levels quicker. India is a dominant manufacturer of hydroxychloroquine because it is an inexpensive drug used to treat malaria, rheumatoid arthritis and lupus. The country has a production capacity of 40 tonnes of hydroxychloroquine (HCQ) every month, implying 200 million tablets of 200 mg each. However, due to increased demand, India has increased the production of Hydroxychloroquine (HCQ) to 300 million tablets from 122.3 million tablets.
The market study is being classified by Type (Hydroxychloroquine 200 mg, Hydroxychloroquine 300 mg and Hydroxychloroquine 400 mg), by Application (Lupus Erythematosus, Rheumatoid Arthritis, COVID-19 and Others) and major geographies with country level break-up.
Zydus Cadila (India), Sanofi S.A. (France), Hikma Pharmaceuticals (United Kingdom), Ipca Laboratories (India), Novartis International AG (Switzerland), Actavis (United States), Apotex Corporation (Canada), Mylan N.V. (United States), ADVANZ PHARMA Corp. (United Kingdom) and Cardinal Health, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sun Pharmaceutical Industries Limited (India), Cinkate Corporation (China), Bristol Laboratories (United Kingdom), Taj Pharmaceuticals (India), Intas Pharmaceuticals (India), McW Healthcare (India), MacleodsPharmaceuticals (India), Cipla (India), Lupin (India), Wallace (India) and Torrent Pharmaceuticals (India.
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Hydroxychloroquine market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Hydroxychloroquine market by Type, Application and Region.
On the basis of geography, the market of Hydroxychloroquine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- High Demand for COVID-19 Treatment from Highly Affected Regions such as the United States, Italy and Others
- Demand for Prevention and Treatment of Malaria
- Increase in the Distribution Channels
- Development of New Hospitals and Clinics
- Increased Research and Development Activities
- Shortage of Hydroxychloroquinev Worldwide
- Fluctuations in the Raw Material Prices
- Growing Number of COVID-19 Infected People Worldwide
- Growing Healthcare Industry
- Rising Applications of Hydroxychloroquine to Treat Various Diseases
- Meet the Rising Demand from Various Countries
- Stringent Government Rules and Regulations of Some Regions
Market Leaders and their expansionary development strategies
Recently, Indian pharmaceutical companies are raising monthly production of anti-malarial drug Hydroxychloroquine (HCQ) four times to 40 metric tonnes (MT) by the end of this month and five to six times to over 70 metric tonnes (MT) by next month. The plan to step up production came after the Government of India indicated it will help countries in dire need of the drug to fight novel coronavirus.
In March 2020, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the United States to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19.
Key Target AudienceHydroxychloroquine Manufacturers, Raw Material Suppliers, Distributors, Research Professionals, Emerging Countries and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase